Reata Pharmaceuticals Top Management
RETADelisted Stock | USD 109.67 3.31 2.93% |
Reata Pharmaceuticals employs about 321 people. The company is managed by 10 executives with a total tenure of roughly 21 years, averaging almost 2.0 years of service per executive, having 32.1 employees per reported executive. Analysis of Reata Pharmaceuticals' management performance can provide insight into the company performance.
Warren Huff Chairman Chairman of the Board and Presidentident, CEO |
Michael Wortley President Vice President Chief Legal Officer |
Reata |
Reata Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.3766) % which means that it has lost $0.3766 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1239) %, meaning that it created substantial loss on money invested by shareholders. Reata Pharmaceuticals' management efficiency ratios could be used to measure how well Reata Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Reata Pharmaceuticals Workforce Comparison
Reata Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 5,899. Reata Pharmaceuticals holds roughly 321 in number of employees claiming about 5% of equities under Health Care industry.
Reata Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Reata Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Reata Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Reata Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Michael Wortley over a year ago Disposition of 49701 shares by Michael Wortley of Reata Pharmaceuticals subject to Rule 16b-3 | ||
Michael Wortley over a year ago Sale by Michael Wortley of 807 shares of Reata Pharmaceuticals | ||
Michael Wortley over a year ago Acquisition by Michael Wortley of 4125 shares of Reata Pharmaceuticals subject to Rule 16b-3 | ||
Michael Wortley over a year ago Sale by Michael Wortley of 894 shares of Reata Pharmaceuticals | ||
Michael Wortley over a year ago Sale by Michael Wortley of 414 shares of Reata Pharmaceuticals | ||
Michael Wortley over a year ago Acquisition by Michael Wortley of 63650 shares of Reata Pharmaceuticals subject to Rule 16b-3 |
Reata Pharmaceuticals Notable Stakeholders
A Reata Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Reata Pharmaceuticals often face trade-offs trying to please all of them. Reata Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Reata Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Warren Huff | Chairman of the Board and Presidentident, CEO | Profile | |
Michael Wortley | Vice President Chief Legal Officer | Profile | |
Christian Wigley | VP Officer | Profile | |
Bhaskar Anand | VP Officer | Profile | |
Dawn Bir | Chief Commercial Officer | Profile | |
Colin MD | Ex Officer | Profile | |
Manmeet Soni | CFO COO | Profile | |
Elaine Castellanos | Consultant | Profile | |
Steve Harman | VP Officer | Profile | |
Dakota Gallivan | VP Officer | Profile |
About Reata Pharmaceuticals Management Performance
The success or failure of an entity such as Reata Pharmaceuticals often depends on how effective the management is. Reata Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Reata management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Reata management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas. Reata Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 346 people.
Please note, the presentation of Reata Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Reata Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Reata Pharmaceuticals' management manipulating its earnings.
Reata Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Reata Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Reata Pharmaceuticals within its industry.Reata Pharmaceuticals Manpower Efficiency
Return on Reata Pharmaceuticals Manpower
Revenue Per Employee | 6.9K | |
Revenue Per Executive | 221.6K | |
Net Loss Per Employee | 971.7K | |
Net Loss Per Executive | 31.2M | |
Working Capital Per Employee | 1.1M | |
Working Capital Per Executive | 33.9M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Reata Stock
If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |